← Back to Clinical Trials
Recruiting NCT06372444

NCT06372444 Mechanisms of Acute Kidney Injury in Severe Infections

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06372444
Status Recruiting
Phase
Sponsor Uppsala University Hospital
Condition Sepsis
Study Type OBSERVATIONAL
Enrollment 15 participants
Start Date 2024-05-01
Primary Completion 2026-04-03

Trial Parameters

Condition Sepsis
Sponsor Uppsala University Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 15
Sex ALL
Min Age 30 Years
Max Age N/A
Start Date 2024-05-01
Completion 2026-04-03
Interventions
Positron emission tomography (PET)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. For marked water will be used for renal perfusion and a newly developed PET tracer molecule (11C-GW457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. The study is performed in a PET-CT camera where anatomical imaging takes place at the same time as the PET examinations.

Eligibility Criteria

Inclusion Criteria: Patients with sepsis and AKI * \> 30 years * At least AKI stage 1 according to KDIGO where the last plasma creatinine is measured within 24 hours of the examination Healthy volunteers * \> 30 years * No previously known kidney disease * Normal plasma creatinine value Exclusion Criteria: * Chronic renal failure (CKD stage \>3a) or dialysis * Instability in vital functions that makes PET-CT examination unsuitable * Claustrophobia or other reasons that make the patient unable to lie still during the examination. * Pregnancy and breastfeeding

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology